Ocugen Inc (OCGN):企業の財務・戦略的SWOT分析

◆英語タイトル:Ocugen Inc (OCGN) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDME6500FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Medical Devices
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD600 ⇒換算¥88,800見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD900 ⇒換算¥133,200見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Ocugen Inc (Ocugen), formerly Histogenics Corp, is a biopharmaceutical company that discovers, develops and commercializes transformative drugs for the treatment of eye diseases. The company’s lead product candidate, OCU300, is a small molecule therapeutic intended for the treatment of ocular graft versus host disease (oGVHD). Ocugen develops its product candidates based on its proprietary OcuNanoE nanoemulsion technology. Its other pipeline products include OCU400, a novel gene therapy product candidate used to restore retinal integrity and function in multiple inherited retinal diseases; and OCU410, a modifier gene therapy product candidate intended to treat dry age-related macular degeneration; and OCU200, a biologic product candidate used to treat patients with diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration. Ocugen is headquartered in Malvern, Pennsylvania, the US.

Ocugen Inc Key Recent Developments

Mar 18,2021: Ocugen Provides Business Update and Full Year 2020 Financial Results
Mar 12,2021: Ocugen to Host Conference Call on Thursday, March 18 at 8:30 a.m. ET to Discuss 2020 Financial Results and Provide a Business Update
Feb 10,2021: Ocugen, Inc. Announces Closing of $23 Million Registered Direct Offering of Common Stock
Feb 07,2021: Ocugen Inc. Announces $23 Million Registered Direct Offering of Common Stock Priced at a Premium to Market
Feb 02,2021: Ocugen and Bharat Biotech Announce Execution of Definitive Agreement for the Commercialization of COVAXIN™ in the US Market

This comprehensive SWOT profile of Ocugen Inc provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Ocugen Inc including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

Ocugen Inc – Key Information
Ocugen Inc – Overview
Ocugen Inc – Key Employees
Ocugen Inc – Key Employee Biographies
Ocugen Inc – Key Operational Heads
Ocugen Inc – Major Products and Services
Ocugen Inc – History
Ocugen Inc – Company Statement
Ocugen Inc – Locations And Subsidiaries
Ocugen Inc
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

Ocugen Inc – Business Description
Ocugen Inc – Corporate Strategy
Ocugen Inc – SWOT Analysis
SWOT Analysis – Overview
Ocugen Inc – Strengths
Ocugen Inc – Weaknesses
Ocugen Inc – Opportunities
Ocugen Inc – Threats
Ocugen Inc – Key Competitors

Section 3 – Company Financial Performance Charts

Ocugen Inc – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

Ocugen Inc, Key Information
Ocugen Inc, Key Ratios
Ocugen Inc, Share Data
Ocugen Inc, Major Products and Services
Ocugen Inc, History
Ocugen Inc, Key Employees
Ocugen Inc, Key Employee Biographies
Ocugen Inc, Key Operational Heads
Ocugen Inc, Other Locations
Ocugen Inc, Subsidiaries
Ocugen Inc, Key Competitors
Ocugen Inc, SWOT Analysis
Ocugen Inc, Ratios based on current share price
Ocugen Inc, Annual Ratios
Ocugen Inc, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Ocugen Inc (OCGN):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • OncoSec Medical Inc (ONCS)-医療機器分野:企業M&A・提携分析
    Summary OncoSec Medical Inc (OncoSec) is a biotechnology company that offers services to stimulate body’s immune system and attack cancer. It’s lead candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through i …
  • Aurobindo Pharma Ltd (AUROPHARMA):企業の財務・戦略的SWOT分析
    Aurobindo Pharma Ltd (AUROPHARMA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • CGN New Energy Holdings Co Ltd (1811):企業の財務・戦略的SWOT分析
    CGN New Energy Holdings Co Ltd (1811) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • Atlantic Airways P/F:戦略・SWOT・企業財務分析
    Atlantic Airways P/F - Strategy, SWOT and Corporate Finance Report Summary Atlantic Airways P/F - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Praxair Inc (PX)-エネルギー分野:企業M&A・提携分析
    Summary Praxair Inc (Praxair) is a producer and supplier of industrial gases. The company offers atmospheric gases including oxygen, nitrogen, argon and rare gases, and process gases such as carbon dioxide, helium, hydrogen, electronic gases, specialty gases and acetylene. It also designs and builds …
  • Bonnier AB:企業の戦略的SWOT分析
    Bonnier AB - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • John Menzies plc:企業の戦略・SWOT・財務情報
    John Menzies plc - Strategy, SWOT and Corporate Finance Report Summary John Menzies plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • CBT Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary CBT Pharmaceuticals Inc (CBT) is a pharmaceutical company that develops innovative medicines for cancer indications. The company's pipeline products include CBT-101, cMet inhibitor is being developed to target the epithelial to mesenchymal transition pathway. Its CBT-101 is developed for var …
  • Vallourec SA:戦略・SWOT・企業財務分析
    Vallourec SA - Strategy, SWOT and Corporate Finance Report Summary Vallourec SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Obsidian Energy Ltd (OBE):石油・ガス:M&Aディール及び事業提携情報
    Summary Obsidian Energy Ltd (Obsidian) is formerly known as Penn West Petroleum Ltd. It is a conventional oil and natural gas production and development company in Canada with a well-balanced portfolio of high-quality assets. It develops and explores oil and gas properties and related production inf …
  • Vonage Holdings Corp.:戦略・SWOT・企業財務分析
    Vonage Holdings Corp. - Strategy, SWOT and Corporate Finance Report Summary Vonage Holdings Corp. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Seabridge Gold Inc.:企業のM&A・事業提携・投資動向
    Seabridge Gold Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Seabridge Gold Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), …
  • Symphony Ltd:企業の戦略・SWOT・財務情報
    Symphony Ltd - Strategy, SWOT and Corporate Finance Report Summary Symphony Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Swadeshi Industrial Works Plc:企業の戦略・SWOT・財務情報
    Swadeshi Industrial Works Plc - Strategy, SWOT and Corporate Finance Report Summary Swadeshi Industrial Works Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Deoleo, S.A.:企業の戦略・SWOT・財務情報
    Deoleo, S.A. - Strategy, SWOT and Corporate Finance Report Summary Deoleo, S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • State Bank of India:企業のM&A・事業提携・投資動向
    State Bank of India - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's State Bank of India Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), …
  • Daisy IT Group Ltd:企業の戦略的SWOT分析
    Daisy IT Group Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • Amcor Limited
    Amcor Limited - Strategy, SWOT and Corporate Finance Report Summary Amcor Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • EFU General Insurance Company Limited:企業の戦略・SWOT・財務情報
    EFU General Insurance Company Limited - Strategy, SWOT and Corporate Finance Report Summary EFU General Insurance Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • HiQ International AB (HIQ):企業の財務・戦略的SWOT分析
    Summary HiQ International AB (HiQ International) is a technology and communication company that offers management consultancy services. The company offers communications solutions, development of software, and business-critical IT systems. It provides services in the areas of telecom media, gaming a …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆